

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, JAPAN, AUSTRALIA OR ANY OTHER JURISDICTION WHERE SUCH ACTION IS SUBJECT TO LEGAL RESTRICTIONS.

Vigmed publishes prospectus concerning the rights issue

For further
information contact:

Chairman of the
board
Lennart Holm
+46 706 30 85 62 or

CEO
Finn Ketler
+46 42 600 53 11

The prospectus concerning Vigmed Holding AB's (publ) ("Vigmed" or the "Company") rights issue has been approved and registered by the Swedish Financial Supervisory Authority and is available on the Company's website www.vigmed.com and on Remium's website www.remium.com.

Vigmed has engaged ABG Sundal Collier as financial advisors and Mannheimer Swartling Advokatbyrå as legal advisor in connection with the rights issue.

For more information, please contact:

Finn Ketler, CEO Vigmed, telephone +46 42 600 53 11, e-mail fk@vigmed.com or Lennart Holm, Chairman of the Board, telephone +46 706 30 85 62.

*Vigmed discloses the information in this press release pursuant to the Swedish Securities Markets Act.
The information was provided for public release on 12 November 2014 at 08:00 CET.*

Vigmed is a Swedish medical technology company whose mission is to eliminate needlestick injuries by offering the market unique needle-protected products. Vigmed is headquartered in Helsingborg, Sweden, and has approximately 20 employees. Vigmed's share is traded on NASDAQ OMX First North in Stockholm (ticker VIG) and has approximately 5,400 shareholders. Remium Nordic AB is the Company's Certified Advisor. Additional information such as company description, a video presentation and risk factors can be found on Vigmed's home page: www.vigmed.com/investor

Important information

This press release is not an offer regarding shares or other securities issued by Vigmed Holding AB (publ) (the “Company”).

This press release may not be distributed in or into the United States, Canada, Japan, Australia or in any other jurisdiction where such action is wholly or partially subject to legal restrictions, or would require additional prospectuses, registration or other measures than those required by Swedish law. Nor may the information in this press release be forwarded or reproduced in a manner that contravenes such restrictions or gives cause to such requirements.

No securities issued by the Company have been or will be registered under the United States Securities Act of 1933, as amended (“Securities Act”) and may not be offered, sold or otherwise transferred, directly or indirectly, in or into the United States except under an available exemption from, or in a transaction not subject to, the registration requirements under the Securities Act. No public offering will be made in the United States.

In member states within the European Economic Area (EEA) (other than Sweden) which have implemented Directive 2003/71/EC (the “Prospectus Directive”), this press release is directed only at qualified investors as defined in the Prospectus Directive.

This press release may contain certain forward-looking statements that reflect the Company’s current views on future events as well as financial and operational performance. Words such as “intend”, “assess”, “expect”, “may”, “plan”, “believe”, “estimate” and other expressions entailing indications or predictions of future development or trends, and which are not based on historical facts, constitute forward-looking statements. Forward-looking statements inherently involve both known and unknown risks and uncertainties as they depend on future events and circumstances. Forward-looking statements information is not a guarantee of future results or performance, and the actual outcome may differ materially from the information set forth in the forward-looking statements.

A prospectus prepared in accordance with the Prospectus Directive have been published on 12 November 2014 and is, with certain restrictions, available at www.vigmed.com.